Compounds and Pharmaceutical Compositions for Uses in Diabetes

1 - 28 . (canceled)

29 . A method for treating diabetes or a diabetes-related disorder, wherein said method comprises administering, to a subject in need of such treatment, a compound represented by Formula 1, or a pharmaceutically acceptable salt thereof:

Cy-Q  Formula 1

wherein

Cy is

where

q is 1, 2 or 3;

→ represents a covalent bond connecting Cy to Q;

A is

1) C 1 -C 6 alkyl,

2) C 2 -C 6 alkenyl,

3) C 1 -C 7 alkyl-Y—,

4) C 1 -C 7 alkyl-OC(O)—, or

5) C 1 -C 7 alkyl-CH(OH)—,

where Y is O, S or C(O);

R 1 , R 2 and R 3 are independently selected from H, F, Cl and OH;

when Cy is Cy1 or Cy2, then Q is

1) C(O)OH,

2) C(CH 3 ) 2 C(O)OH,

3) (CH 2 )mC(O)OH,

4) ZCH(C(O)OH)C 1 -C 8 alkyl,

5) Z(CH 2 )mC(O)OH, or

6) CH 2 CH(C(O)OH)C 1 -C 8 alkyl,

where

Z is O or S,

m is 1 or 2; and

when Cy is Cy3, then Q is C(O)OH.

30 . The method of claim 29 , wherein the compound is represented by Formula 1A, or a pharmaceutically acceptable salt thereof:

wherein

A is

1) C 1 -C 6 alkyl, or

2) C 1 -C 6 alkenyl;

R 1 and R 2 are independently selected from H, F, Cl and OH;

Q is

1) C(O)OH,

2) C(CH 3 ) 2 C(O)OH, or

3) (CH 2 )mC(O)OH,

where m is 1 or 2.

31 . The method of claim 29 , wherein the compound is represented by Formula 1B, or a pharmaceutically acceptable salt thereof:

wherein

A is

1) C 1 -C 6 alkyl, or

2) C 1 -C 6 alkenyl;

Q is

1) C(O)OH, or

2) (CH 2 )mC(O)OH,

where m is 1 or 2;

wherein

A is

3) C 1 -C 6 alkyl, or

4) C 1 -C 6 alkenyl;

Q is

3) C(O)OH, or

4) (CH 2 )mC(O)OH,

where m is 1 or 2.

32 . The method of claim 29 , wherein the compound is represented by Formula 1C, or a pharmaceutically acceptable salt thereof:

wherein

n is 2, 3, 4, 5 or 6;

R is —C(O)—, —OC(O)—, —CH(OH)—, or O;

A is YCH(C(O)OH)(CH 2 ) p CH 3 when B is H;

B is YCH(C(O)0H)(CH 2 ) p CH 3 when A is H; or A and B are covalently bonded to form a 5-, 6- or 7-membered cycloalkyl substituted with a C(O)OH group;

where

Y is O, S or CH 2 , and

p is 1, 2, 3, 4, 5, 6 or 7.

33 . The method of claim 29 , wherein the pharmaceutically acceptable salt is a base addition salt.

34 . The method of claim 33 , wherein the base addition salt comprises a metal counterion selected from sodium, potassium, magnesium, calcium and lithium.

35 . The method of claim 29 , wherein the compound is any one of Compounds I-XVII, XIX-XXVII and XXIX-XXXIV:

Compound

Structure

I

II

III

IV

V

VI

VII

VIII

IX

X

XI

XII

XIII

XIV

XV

XVI

XVII

XVIII

XIX

XX

XXI

XXII

XXIII

XXIV

XXV

XXVI

XXVII

XXVIII

XXIX

XXX

XXXI

XXXII

XXXIII

XXXIV

36 . The method of claim 35 , wherein the compound is Compound I, II, V, VIII, XIV, XXIII or XXVI.

37 . The method of claim 35 , wherein the compound is Compound I.

38 . The method of claim 35 , wherein the compound is Compound XIV.

39 . The method of claim 29 , wherein said diabetes or diabetes-related disorder is Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema or a renal disorder.

40 . The method of claim 39 , wherein the diabetes is Type II diabetes.

41 . The method of claim 39 , wherein the diabetes-related disorder is diabetic nephropathy.

42 . The method of claim 39 , wherein the diabetes-related disorder is proteinuria.

43 . The method of claim 39 , wherein the diabetes-related disorder is ketonuria.

44 . The method of claim 29 , wherein said use is also for decreasing ketone bodies in the urine of a subject in need thereof.

45 . The method of claim 29 , wherein said use is also for increasing glomerular filtration rate (GFR) in a subject in need thereof.

46 . The method of claim 29 , wherein said use is also for increasing insulin secretion or increasing insulin sensitivity in a subject in need thereof.

47 . The method of claim 29 , wherein said use is also for decreasing insulin resistance in a subject in need thereof.

48 . The method of claim 29 , wherein said use is also for decreasing hyperglycemia in a subject in need thereof.

49 . The method of claim 29 , wherein the compound is used in combination with a therapeutic agent for lowering or controlling blood glucose level.

50 . The method of claim 49 , wherein the therapeutic agent is metformin or thiazolidinedione.

51 . A pharmaceutical composition comprising a compound as defined in claim 29 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

52 . The pharmaceutical composition of claim 51 , further comprising a therapeutic agent for lowering or controlling blood glucose level.

53 . The pharmaceutical composition of claim 53 , wherein the therapeutic agent is metformin or a thiazolidinedione.

54 . The pharmaceutical composition of claim 51 , wherein the composition is adapted for oral administration.